# Aetion a Datavant Company

> Aetion is a healthcare evidence software and scientific services business acquired by Datavant in 2025. Its Aetion Evidence Platform and applications help biopharma companies, medical device manufacturers, payers and regulators explore healthcare data and generate transparent, reproducible evidence about treatment safety, effectiveness and value.

- **Founded:** 2013
- **Headquarters:** New York, United States
- **Founders:** Jeremy Rassen (Co-founder; former CEO and CTO), Sebastian Schneeweiss (Co-founder; scientific advisor)
- **Products:** Aetion Evidence Platform, Aetion Discover, Aetion Substantiate, Aetion Activate, Aetion Generate
- **Notable:** USD 110 million Series C in May 2021., Reported nearly doubled revenue and 100% customer renewals in the year preceding its 2021 financing announcement., AEP used in RCT-DUPLICATE implementation; 2023 JAMA publication reported results from 32 selected clinical-trial emulations.

## Products & services

- **Aetion Evidence Platform** — Core technology for transparent, reproducible real-world healthcare data analyses using epidemiology and causal inference.
- **Aetion Discover** — Exploratory and descriptive analytics for population characteristics, treatment patterns, dataset assessment and hypothesis generation.
- **Aetion Substantiate** — Application for decision-grade descriptive and causal analyses with methodological traceability.
- **Aetion Activate** — Low-code data preparation plus a hosted coding environment, reusable definitions, versioning and audit trails; announced in May and launched in August 2025.
- **Aetion Generate** — Privacy-enhancing synthetic data and related privacy and data utility capabilities, developed from Replica Analytics technology.
- **Scientific and evidence services** — Study design, data fitness assessment, regulatory evidence support, clinical development analytics and market access research.

## Achievements

- USD 110 million Series C in May 2021.
- Reported nearly doubled revenue and 100% customer renewals in the year preceding its 2021 financing announcement.
- AEP used in RCT-DUPLICATE implementation; 2023 JAMA publication reported results from 32 selected clinical-trial emulations.
- Acquired Replica Analytics in January 2022.
- Joined Datavant in 2025.

## Latest updates

- **2026-07** — Datavant described an integrated approach pairing data linkage with fit-for-purpose evidence design and targeted data enrichment.
- **2026-04** — Datavant described development and deployment of human-supervised agents across Datavant Connect and AEP; this is a company-described approach, not independent performance validation.
- **2025-08** — Activate launched with low-code data preparation, hosted coding, versioning and audit trails.
- **2025-07** — Aetion publicly confirmed that its acquisition by Datavant was complete.
- **2025-05** — Datavant announced an agreement to acquire Aetion; official announcement did not disclose financial terms.

## Links

- Website: https://aetion.com/
- LinkedIn: https://www.linkedin.com/company/aetion-inc-/
- Twitter/X: https://twitter.com/aetioninc

---

Profile page: https://yespress.io/aetion-a-datavant-company
Published by YesPress — https://yespress.io
Last updated: 2026-10-01